Q1 2026 EPS Estimates for Sarepta Therapeutics, Inc. Reduced by Analyst (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Analysts at Zacks Research lowered their Q1 2026 earnings per share (EPS) estimates for Sarepta Therapeutics in a research report issued to clients and investors on Tuesday, April 23rd. Zacks Research analyst S. Ganoria now forecasts that the biotechnology company will post earnings per share of $2.01 for the quarter, down from their previous forecast of $2.09. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.13 per share.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported $0.47 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.50. Sarepta Therapeutics had a negative return on equity of 18.97% and a negative net margin of 43.11%. The company had revenue of $396.80 million for the quarter, compared to analyst estimates of $387.18 million. During the same period last year, the company posted ($1.24) earnings per share. The firm’s revenue was up 53.6% compared to the same quarter last year.

A number of other analysts have also issued reports on SRPT. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $128.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, February 29th. Needham & Company LLC dropped their target price on Sarepta Therapeutics from $169.00 to $166.00 and set a “buy” rating on the stock in a research report on Thursday, February 29th. Mizuho lifted their target price on Sarepta Therapeutics from $130.00 to $145.00 and gave the stock a “buy” rating in a research report on Wednesday, February 14th. Barclays lifted their target price on Sarepta Therapeutics from $141.00 to $185.00 and gave the stock an “overweight” rating in a research report on Thursday, February 29th. Finally, Wedbush reaffirmed an “outperform” rating and set a $224.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, February 29th. Four research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat, Sarepta Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $158.38.

Sarepta Therapeutics Stock Up 2.5 %

Shares of NASDAQ SRPT opened at $127.39 on Wednesday. Sarepta Therapeutics has a 1 year low of $55.25 and a 1 year high of $159.89. The firm has a market cap of $11.96 billion, a price-to-earnings ratio of -20.82 and a beta of 0.94. The company has a debt-to-equity ratio of 1.32, a quick ratio of 3.45 and a current ratio of 3.95. The stock’s 50-day simple moving average is $126.22 and its 200-day simple moving average is $110.43.

Hedge Funds Weigh In On Sarepta Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Mather Group LLC. acquired a new position in shares of Sarepta Therapeutics during the first quarter worth approximately $28,000. Montag A & Associates Inc. bought a new stake in Sarepta Therapeutics during the third quarter worth approximately $30,000. Cary Street Partners Investment Advisory LLC raised its holdings in Sarepta Therapeutics by 154.0% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 154 shares in the last quarter. Principal Securities Inc. bought a new stake in Sarepta Therapeutics during the fourth quarter worth approximately $26,000. Finally, GAMMA Investing LLC raised its holdings in Sarepta Therapeutics by 37.0% during the first quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 87 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 761 shares of Sarepta Therapeutics stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $122.93, for a total value of $93,549.73. Following the completion of the transaction, the director now directly owns 7,516 shares in the company, valued at $923,941.88. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, insider Bilal Arif sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $128.84, for a total transaction of $257,680.00. Following the completion of the transaction, the insider now directly owns 26,836 shares in the company, valued at $3,457,550.24. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Kathryn Jean Boor sold 761 shares of the business’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $122.93, for a total value of $93,549.73. Following the transaction, the director now owns 7,516 shares of the company’s stock, valued at $923,941.88. The disclosure for this sale can be found here. Insiders sold a total of 22,096 shares of company stock worth $2,739,419 over the last ninety days. Company insiders own 7.40% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.